Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
biokangtai.com

See what CB Insights has to offer

Founded Year

1988

Stage

IPO | IPO

Total Raised

$26.4M

Date of IPO

2/7/2017

About BioKangtai

Manufacturer of biological products in China. The company manufactures hepatitis B vaccine that prevents liver cancer. The products are distributed in 31 provinces.

BioKangtai Headquarter Location

6 Kefa Road Science & Industry Park, Nanshan

Shenzhen, Guangdong, 518057,

China

86 755 26988688

Latest BioKangtai News

Biokangtai: Recombinant COVID-19 Vaccine(Adenovirus Vector) Licensed For Manufacturing, Which Actively Promotes Vaccine Export And Improves Vaccine Accessibility

Sep 9, 2021

Biokangtai: Recombinant COVID-19 Vaccine(Adenovirus Vector) Licensed For Manufacturing, Which Actively Promotes Vaccine Export And Improves Vaccine Accessibility SHENZHEN, China, Sept. 8, 2021 /PRNewswire/ -- The other day Shenzhen Kangtai Biological Products Co. Author: Sep 8, 2021 11:40 PM EDT SHENZHEN, China, Sept. 8, 2021 /PRNewswire/ -- The other day Shenzhen Kangtai Biological Products Co., Ltd. announced that the company and AstraZeneca signed the " Amendment 1 to License Agreement". In addition to authorizing BIOKANGTAI to commercialize its  Recombinant COVID-19 Vaccine (Adenovirus Vector)  in Chinese mainland, AstraZeneca has also authorized BIOKANGTAI to commercialize the vaccine in Pakistan and Indonesia. AstraZeneca provides the necessary support for BIOKANGTAI to obtain emergency use and marketing authorization in the licensed areas. BIOKANGTAI has also recently renewed the "Manufacturing License" to extend the scope of manufacturing at the company's Shenzhen Guangming Base: Recombinant COVID-19 Vaccine (Adenovirus Vector). According to the statistics of Our World in  Data, as of September 2, 2021, Recombinant COVID-19 Vaccine (Adenovirus Vector) jointly developed by AstraZeneca and University of Oxford has been approved for use in 185 countries around the world. Previously, in August 2020, BIOKANGTAI and AstraZeneca signed the "License Agreement", and AstraZeneca exclusively authorized BIOKANGTAI to develop, manufacture and commercialize Recombinant COVID-19 Vaccine (Adenovirus Vector) in Chinese mainland; in November  2020, both parties unveiled Recombinant COVID-19 Vaccine (Adenovirus Vector) manufacturing workshop together at the 3rd China International Import Expo; in February 2021, trial production was started at the workshop. Through the signing of this Amendment, BIOKANGTAI and AstraZeneca will expand the commercialization of Recombinant COVID-19 Vaccine (Adenovirus Vector) to overseas  market, laying a foundation for the local registration and sales of the product. Meanwhile, BIOKANGTAI also has sufficient manufacturing capacity and conditions, and is expected to export  the finished products to Indonesia, Pakistan and other countries in the future,  which will ease the shortage of vaccine supply, and contribute to improving the accessibility and affordability of vaccines worldwide, especially in developing countries. View original content: https://www.prnewswire.com/news-releases/biokangtai-recombinant-covid-19-vaccineadenovirus-vector-licensed-for-manufacturing-which-actively-promotes-vaccine-export-and-improves-vaccine-accessibility-301372065.html

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BioKangtai

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioKangtai is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

BioKangtai Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BioKangtai Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.